Medline Inc.
Bear Case (25th pct.)
-51.9% vs price
Base Case (Median)
-42.3% vs price
Bull Case (75th pct.)
-33.2% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-3.25 | -109.3% | High (40%) |
| PE Comparable | $19.14 | -45.1% | Medium (25%) |
| Graham Number | $16.00 | -54.1% | Medium (40%) |
| EV/EBITDA | $24.04 | -31.1% | Medium (20%) |
| EV/FCF | $49.90 | 43.1% | Medium (20%) |
| Earnings Power Value | $21.08 | -39.6% | Medium (50%) |
Based on 6 out of 8 methods, MDLN appears overvalued at the current price of $34.88. The base case fair value of $20.11 implies 42.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.